Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of anti-Mucin-1 (F1C) CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Mucin-1 Protein, His Tag (Cat. No. MU1-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
Mouse Mucin-1 (21-535) Protein, His Tag (Cat. No. MU1-M52H4) immobilized on CM5 Chip can bind anti-mMUC1-mAb with an affinity constant of 302 nM as determined in a SPR assay (Biacore 8K) (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma | Details |
| Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
| Adenoviral MUC1 vaccine (Etubics) | ETBX-061; Ad5-MUC1 | Phase 2 Clinical | Etubics Corp, Immunitybio Inc, Nantkwest Inc | Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell | Details |
| GO-2032c | GO-203-2C | Phase 2 Clinical | Genus Oncology Llc, Dana-Farber Cancer Institute | Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BLP25 liposome vaccine | BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 | Phase 2 Clinical | Cascadian Therapeutics Inc | Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DS-3939 | DS-3939; DS-3939a | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours; Neoplasm Metastasis | Details |
| BromAc | Phase 2 Clinical | Mucpharm Pty Ltd | Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated | Details | |
| BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
| huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies | Breast Neoplasms | Details |
| Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details | |
| Gatipotuzumab | GT-MAB-2.5-GEX | Phase 1 Clinical | Nemod, Glycotope Gmbh | Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
| DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Ovarian Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Solid tumours; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Melanoma | Details |
| Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) | Phase 2 Clinical | Guangzhou Anjie Biomedical Technology | Esophageal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
| Anti-MUC1 monoclonal antibody (OncoQuest) | AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 | Phase 2 Clinical | Altarex | Pancreatic Neoplasms | Details |
| Adenoviral MUC1 vaccine (Etubics) | ETBX-061; Ad5-MUC1 | Phase 2 Clinical | Etubics Corp, Immunitybio Inc, Nantkwest Inc | Chordoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell | Details |
| GO-2032c | GO-203-2C | Phase 2 Clinical | Genus Oncology Llc, Dana-Farber Cancer Institute | Solid tumours; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
| MUC1-Poly-ICLC | MUC1-poly-ICLC | Phase 2 Clinical | University Of Pittsburgh | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BLP25 liposome vaccine | BLP-25; L-BLP25; ONO-7165; LP-BLP-25; EMD-531444 | Phase 2 Clinical | Cascadian Therapeutics Inc | Rectal Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| DS-3939 | DS-3939; DS-3939a | Phase 2 Clinical | Daiichi Sankyo Inc | Solid tumours; Neoplasm Metastasis | Details |
| BromAc | Phase 2 Clinical | Mucpharm Pty Ltd | Coronavirus Disease 2019 (COVID-19); Pneumonia, Ventilator-Associated | Details | |
| BM7PE | Phase 2 Clinical | Oslo University Hospital | Colorectal Neoplasms | Details | |
| Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) | Phase 2 Clinical | The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney | Carcinoma, Non-Small-Cell Lung | Details | |
| huMNC2-CAR44 | huMNC2-CAR44 | Phase 1 Clinical | Minerva Biotechnologies | Breast Neoplasms | Details |
| Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms | Details | |
| Gatipotuzumab | GT-MAB-2.5-GEX | Phase 1 Clinical | Nemod, Glycotope Gmbh | Solid tumours; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| P-MUC1C-ALLO1 | P-MUC1C-ALLO1; P-MUC1C-101 | Phase 1 Clinical | Poseida Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Nasopharyngeal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| MUC1-peptide-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| MUC1-gene-DC-CTL (Beijing Doing Biomedical) | Phase 1 Clinical | Beijing Doing Biomedical Co Ltd | Stomach Neoplasms | Details | |
| Recombinant HSP-MUC1 fusion protein (Newsummit) | Phase 1 Clinical | Shanghai Xinshengyuan Biological Medicine Co Ltd | Breast Neoplasms | Details | |
| DXC-005 | DXC-005 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours | Details |
| M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| ICTCAR-046 | ICTCAR-046 | Clinical | Innovative Cellular Therapeutics Co Ltd | Pancreatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
